Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®

Exclusion Criteria

• •Women of childbearing potential who are pregnant, breastfeeding, or do not agree to use an adequate birth control method throughout the study;
• •Any form of glaucoma other than open angle glaucoma or ocular hypertension;
• •Severe central visual field loss;
• •Chronic, recurrent, or severe inflammatory eye disease;
• •Ocular trauma within the past 6 months;
• •Ocular infection or ocular inflammation within the past 3 months;
• •Best-corrected visual acuity score worse than approximately 20/80 Snellen;
• •Eye surgery within the past 6 months;
• •Any condition, including severe illness, which would make the subject unsuitable for the study in the opinion of the Investigator;
• •Use of any additional topical or systemic ocular hypertensive medication during the study;
• •Patients who, in the opinion of the Investigator, cannot discontinue all IOP-lowering ocular medication(s) per the appropriate washout schedule prior to Eligibility 1 Visit;